Analysis from the CD TREAT registry (Crohn’s Therapy, Resource, Evaluation and Assessment Tool), which incorporates data on more than 3000 patients on anti-TNF therapy, revealed that infliximab-treated patients displayed a significantly increased risk of serious infections compared with the ‘other treatments-only’ group (hazard ratio = 1.45, p = 0.008). Here, TNF is linked to infection.